CA3017760A1 - Compositions and methods for stimulating clearance of amyloid-.beta. protein - Google Patents

Compositions and methods for stimulating clearance of amyloid-.beta. protein Download PDF

Info

Publication number
CA3017760A1
CA3017760A1 CA3017760A CA3017760A CA3017760A1 CA 3017760 A1 CA3017760 A1 CA 3017760A1 CA 3017760 A CA3017760 A CA 3017760A CA 3017760 A CA3017760 A CA 3017760A CA 3017760 A1 CA3017760 A1 CA 3017760A1
Authority
CA
Canada
Prior art keywords
agonist
amyloid
subject
composition
degradation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3017760A
Other languages
English (en)
French (fr)
Inventor
Kalipada PAHAN
Arunava Ghosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rush University Medical Center
Original Assignee
Rush University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rush University Medical Center filed Critical Rush University Medical Center
Publication of CA3017760A1 publication Critical patent/CA3017760A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3017760A 2016-03-15 2017-03-10 Compositions and methods for stimulating clearance of amyloid-.beta. protein Pending CA3017760A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308374P 2016-03-15 2016-03-15
US62/308,374 2016-03-15
PCT/US2017/021799 WO2017160629A1 (en) 2016-03-15 2017-03-10 COMPOSITION AND METHODS FOR STIMULATING CLEARANCE OF AMYLOID-β PROTEIN

Publications (1)

Publication Number Publication Date
CA3017760A1 true CA3017760A1 (en) 2017-09-21

Family

ID=59852353

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3017760A Pending CA3017760A1 (en) 2016-03-15 2017-03-10 Compositions and methods for stimulating clearance of amyloid-.beta. protein

Country Status (5)

Country Link
US (2) US11135180B2 (enExample)
EP (1) EP3429671B1 (enExample)
JP (1) JP7012658B2 (enExample)
CA (1) CA3017760A1 (enExample)
WO (1) WO2017160629A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111084768A (zh) 2018-10-24 2020-05-01 中国科学院昆明动物研究所 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途
EP3999051B1 (en) * 2019-07-16 2025-07-09 Rush University Medical Center Inhalation dosage forms of glycerol tribenzoate and/or glycerol dibenzoate for use in the treatment of huntington's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60216275T2 (de) * 2001-05-25 2007-06-21 Schering Corp. Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US9750712B2 (en) * 2012-12-07 2017-09-05 Rush University Medical Center Composition and method for treating neuronal ceroid lipofuscinosis
US20150320706A1 (en) * 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
WO2016201086A1 (en) * 2015-06-12 2016-12-15 Rush University Medical Center Compositions and methods for stimulating adam10-mediated nonamyloidogenic proteolysis of amyloid precursor protein

Also Published As

Publication number Publication date
EP3429671A4 (en) 2019-10-16
JP2019512507A (ja) 2019-05-16
EP3429671B1 (en) 2024-05-01
JP7012658B2 (ja) 2022-02-14
EP3429671A1 (en) 2019-01-23
US11844767B2 (en) 2023-12-19
US11135180B2 (en) 2021-10-05
US20200297657A1 (en) 2020-09-24
US20210401772A1 (en) 2021-12-30
WO2017160629A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
CN102065897B (zh) 基于磺胺异噁唑的组合物用于制备治疗阿茨海默病的药物的应用
Sivak The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease
CN102065858B (zh) 使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物
JP7385924B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物
Zhao et al. High glucose‐induced complement component 3 up‐regulation via RAGE‐p38 MAPK‐NF‐κB signalling in astrocytes: In vivo and in vitro studies
CN114042061A (zh) 包含色甘酸的组合物在制备用于治疗非遗忘性轻度认知障碍的药物中的用途
US11844767B2 (en) Composition and methods for stimulating clearance of amyloid-beta protein
US20240269124A1 (en) Methods and compositions for treating neurological conditions
WO2020165802A1 (en) Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
CN109069450A (zh) 神经障碍的新的组合疗法
JP7249433B2 (ja) 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
CN114521142A (zh) 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法
US20130303564A1 (en) Method for treating a neurodegenerative disorder
US20240238268A1 (en) Treatments and methods for treating alzheimer's disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220301

EEER Examination request

Effective date: 20220301

EEER Examination request

Effective date: 20220301

EEER Examination request

Effective date: 20220301

EEER Examination request

Effective date: 20220301